- Home
- PMCB vs DRCT Comparison
PMCB vs DRCT Comparison
Compare PMCB & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- DRCT
- Stock Information
- Founded
- PMCB 1996
- DRCT 2018
- Country
- PMCB United States
- DRCT United States
- Employees
- PMCB N/A
- DRCT N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- DRCT Computer Software: Programming Data Processing
- Sector
- PMCB Health Care
- DRCT Technology
- Exchange
- PMCB Nasdaq
- DRCT Nasdaq
- Market Cap
- PMCB 11.4M
- DRCT 10.4M
- IPO Year
- PMCB N/A
- DRCT 2022
- Fundamental
- Price
- PMCB $1.22
- DRCT $0.67
- Analyst Decision
- PMCB
- DRCT
- Analyst Count
- PMCB 0
- DRCT 0
- Target Price
- PMCB N/A
- DRCT N/A
- AVG Volume (30 Days)
- PMCB 14.5K
- DRCT 1.1M
- Earning Date
- PMCB 03-17-2025
- DRCT 03-27-2025
- Dividend Yield
- PMCB N/A
- DRCT N/A
- EPS Growth
- PMCB N/A
- DRCT N/A
- EPS
- PMCB 1.29
- DRCT N/A
- Revenue
- PMCB N/A
- DRCT $62,288,000.00
- Revenue This Year
- PMCB N/A
- DRCT $53.01
- Revenue Next Year
- PMCB N/A
- DRCT $11.11
- P/E Ratio
- PMCB $0.93
- DRCT N/A
- Revenue Growth
- PMCB N/A
- DRCT N/A
- 52 Week Low
- PMCB $1.03
- DRCT $0.44
- 52 Week High
- PMCB $2.42
- DRCT $7.68
- Technical
- Relative Strength Index (RSI)
- PMCB 43.93
- DRCT 50.52
- Support Level
- PMCB $1.15
- DRCT $0.53
- Resistance Level
- PMCB $1.32
- DRCT $0.74
- Average True Range (ATR)
- PMCB 0.11
- DRCT 0.10
- MACD
- PMCB 0.02
- DRCT 0.02
- Stochastic Oscillator
- PMCB 65.52
- DRCT 77.42
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.